Digoxin Poisoning Management

- Digoxin is a cardioactive glycoside indicated for atrial flutter, atrial fibrillation, and heart failure
- Acts as a sodium/potassium pump inhibitor for cardiac myocytes → toxicity arises with too much intracellular Na+ inhibiting the sodium/calcium pump from working properly (increasing intracellular calcium)
- Increased inotropy within the cardiac myocytes → dysrhythmias
- EKG abnormalities: premature ventricular contractions, biphasic T wave, shortened QT interval, AV block
- Digoxin therapeutic levels range from 0.8-2.0 ng/ml (toxicity can begin >2 ng/ml)
Pharmacology
Digoxin Immune Fab (DigiFab or DigiBind) | |
Dose |
1 vial = 40mg (binds to 0.5mg of digoxin)
|
Administration | IV infusion over 30 minutes If cardiac arrest is imminent a bolus injection can be given |
PK/PD | Onset: 20-90 minutes Duration of action: 15 – 20 hrs |
Adverse Effects | Orthostatic hypotension, ventricular tachycardia, hypokalemia |
Mechanism of Action | Immune antigen-binding fragments that rapidly bind with digoxin to decrease free digoxin levels within the body |
Compatibility | 0.9% NS Only |
Comments | Monitor K+ closely as it shifts intracellularly potentially causing hypokalemia.Total concentration of digoxin may be falsely elevated after administration due to in free drug & bounded drug.Free digoxin concentrations are more clinically useful |
Overview of Evidence
Author, year | Design/ sample size | Intervention & Comparison | Outcome |
Wei et al., 2021 | Case reports (n=121) | DigiBind vs DigiFab adverse events reported to FAERS from 1986-2019 | 87.2% of DigiBind reports were serious AEs vs. 62.8% of DigiFabHypotension, cardiac arrest, and death were among the most serious AEs |
Ward et al, 2000 | Observational (n=16) | DigiBind vs DigiFab in healthy volunteers | Both Fab products reduced free digoxin serum concentrations to below assay detection Total digoxin serum concentrations increased approximately 10-fold (indicated fab product binding digoxin) |
Renard et al., 1997 | Observational (n=16) | Influence of age & renal dysfunction on digoxin-specific Fab pharmacokinetics •Doses 80-800mg infused over 0.25-2hr •Patients aged 35-90 with CrCl 10.6-122.1 ml/min | Linear decrease of total body clearance is linked to renal function and age, but not VdPlasma half-lives ranged from 11-34.5hrsAll patients recovered and no adverse effects were reported |
Antman et al., 1990 | Open-label trial (n=150) | Digoxin-specific Fab fragment dosed based on total ingested amount (mg) or digoxin serum concentration (ng/ml) | 90% of patient toxicity resolved or improved with 10% showing no response Median dose ~ 200mg (5 vials)Highest dose ~ 1600mg (40 vials) |
Conclusions
- Digoxin toxicity is a serious & life-threatening condition if not appropriately reversed by an available antidote
- For unknown amount of ingestion, administer 10 vials of digoxin Immune Fab to treat digoxin toxicity
- Age and renal function are proven not to be factors prohibiting digoxin toxicity treatment
References
- Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-162. doi:10.3109/15563657308990513
- David MNV, Shetty M. Digoxin. [Updated 2022 Sep 5]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556025/
- Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; January 2023. Accessed January 16, 2023. https://online.lexi.com.
- Antman et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-1752. doi:10.1161/01.cir.81.6.1744
- Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol. 1997;44(2):135-138. doi:10.1046/j.1365-2125.1997.00654.x
- Roberts DM, Gallapatthy G, Dunuwille A, Chan BS. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2016;81(3):488-495. doi:10.1111/bcp.12814
- Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28(6):483-493. doi:10.2165/00003088-199528060-00006
- Wei, S., Niu, M.T. & Dores, G.M. Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019. Drugs – Real World Outcomes 8, 253–262 (2021). https://doi.org/10.1007/s40801-021-00242-x
- Ward SB, Sjostrom L, Ujhelyi MR. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther Drug Monit. 2000 Oct;22(5):599-607. doi: 10.1097/00007691-200010000-00016. PMID: 11034267.
Related Articles
PPIs for the Management of Upper GI Bleed
Introduction Upper GI bleed (UGIB) is a common reason for ED visits with a major cause of morbidity, mortality and medical care costs. Peptic ulcer…
Nielsen N, et al. “Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest”. The New England Journal of Medicine. 2013. 369(23):2197-2206.
Interactive Guide to Hyperglycemic Crises Interactive Guide to Hyperglycemic Crises DKA & HHS: Diagnosis and Management Insights (2024 Consensus Update) Introduction Understanding Diagnosis Management Algorithm…
Holzer M, et al. “Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest”. The New England Journal of Medicine. 2002. 346(8):549-556.
PACULit Summary: Mild Therapeutic Hypothermia to Improve Neurologic Outcome After Cardiac Arrest Resources PubMed Full Text Contents Article Identification Quick Reference Summary Core Clinical Question…
Clinical Efficacy of Beta-1 Selective Beta-Blockers Versus Propranolol in Patients With Thyroid Storm: A Retrospective Cohort Study
Table of Contents Pharmacy & Acute Care University Contents Article Identification Quick Reference Summary Core Clinical Question Background Methods Summary Detailed Results Authors’ Conclusions Critical…
Echt DS, et al. “Mortality and morbidity in patients receiving encainide, flecainide, or placebo”. The New England Journal of Medicine. 1991. 324(12):781-788.
PACULit Summary – Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo Resources PubMed Full Text Contents Article Identification Quick Reference Summary Core Clinical…
Responses